Wow! This is a great move by AGN's Mgmt to add another growth engine, and a beautiful fit, to it's Aesthetic business.
SkinMedica brings a great complement of products and offerings to Allergan's global leadership in the Aesthetic industry.
It comes at a very appropriate time when SkinMedica is expanding it's international reach.
This is such a HUGE win-win and; more importantly, a great addition to Allergan's growth strategy.
Harm0nicsa, it seems like your rigorous "dcf valuation & technical momentum assessments mechanism" has diverted your perception from the simplicity of the obvious.
AGN has been one of the top plays in the unique hybrid-pharma sector. It has earned it's 26X P/E; delivering 5 years, of 14 percent EPS growth and it's forward P/E of 18-20X will keep it an attractive buy to most prudent investors.
Your macro economic prognostication is extremely bearish and misses the mark on the current econ-environment.
May I suggest you expand your model to include; AGN's mgmt, products and performance and perhaps you will gain greater insight.
How did you figure that out? What criteria? Agreed, it is difficult to evaluate at times given pipelines in progress and acquisitions they do from time to time. Fiscal cliff distorts so many things right now.
I agree. This is a good positive development that will contribute well into the future revenue stream.
I kind of lucked out in getting some profits earlier in the month and yesterday moved back in and did good today with the conciliation news from Wash DC with the politicians. After all of the dust settles, then, we see a strong company working itself up higher again.